Диссертация (1154734), страница 15
Текст из файла (страница 15)
36.53.Dammacco F. HCV infection and cruoglobulinemia // Springer. 2012. P. 359.54.Ferri C., M. Sebastiani, D. Giuggioli, et al. Mixed cryoglobulinemia:demographic, clinical, and serologic features and survival in 231 patients // SeminArthritis Rheum. 2004. Vol. 33, № 6. P. 355-374.55.Гордовская Н.Б. Козловская Л.В., Азарова В.В.
и др. Особенностиклиническоготечениянефритаубольныхскриоглобулинемией.//Терапевтический архив. 1997. Том 6, С. 30-34.56.Мухин Н.А. Козловская .Л.В., Малышко Е.Ю. Криоглобулинемическийнефрит, ассоциированный с хронической инфекцией вируса гепатита С. //Терапевтический архив. 2000.
Том 6, С. 1-5.57.КозловскаяЛ.В.,ГордовскаяН.Б.,МалышкоЕ.Ю.идр.Криоглобулинемическое поражение почек: особенности течения и лечение// Нефрология и диализ. 2002. Том. 4, № 1. С. 4-8.58.КозловскаяЛ.В.,ГордовскаяН.Б.,МухинН.А.Факторырискапрогрессирования криоглобулинемического гломерулонефрита, связанногос вирусом гепатита С // Клиническая медицина. 2001. Том. 4, С. 32-35.59.Perl A., P.D. Gorevic, D.H. Ryan, et al.
Clonal B cell expansions in patients withessential mixed cryoglobulinaemia // Clin Exp Immunol. 1989. Vol. 76, № 1. P.54-60.60.Pozzato G., C. Mazzaro, M. Crovatto, et al. Low-grade malignant lymphoma,hepatitis C virus infection, and mixed cryoglobulinemia // Blood. 1994. Vol. 84,№ 9. P.
3047-3053.61.Ferri C., F. Caracciolo, A.L. Zignego, et al. Hepatitis C virus infection in patientswith non-Hodgkin's lymphoma // Br J Haematol. 1994. Vol. 88, № 2. P. 392-394.62.Fiorino S., L. Bacchi-Reggiani, D. de Biase, et al. Possible association betweenhepatitis C virus and malignancies different from hepatocellular carcinoma: Asystematic review // World J Gastroenterol. 2015. Vol. 21, № 45. P.12896-12953.9763.Allison R.D., X. Tong, A.C.
Moorman, et al. Increased incidence of cancer andcancer-related mortality among persons with chronic hepatitis C infection, 20062010 // J Hepatol. 2015. Vol. 63, № 4. P. 822-828.64.Zignego A.L., C. Giannini,L. Gragnani. HCV and lymphoproliferation // ClinDev Immunol. 2012. Vol. 2012, P. 980942.65.Игнатова Т.М.Современные возможности лечения криоглобулинемическоговаскулита и В-клеточной лимфомы, обусловленных вирусом гепатита С //Терапевтический архив.
2012. Том 84, № 11. С. 81-88.66.Monti G., P. Pioltelli, F. Saccardo, et al. Incidence and characteristics of nonHodgkin lymphomas in a multicenter case file of patients with hepatitis C virusrelated symptomatic mixed cryoglobulinemias // Arch Intern Med. 2005. Vol.165, № 1. P. 101-105.67.Gusella J.F., N.S. Wexler, P.M.
Conneally, et al. A polymorphic DNA markergenetically linked to Huntington's disease // Nature. 1983. Vol. 306, № 5940. P.234-238.68.Auton A., L.D. Brooks, R.M. Durbin, et al. A global reference for human geneticvariation // Nature. 2015. Vol. 526, № 7571.
P. 68-74.69.The International HapMap Project // Nature. 2003. Vol. 426, 6968. P. 789-796.70.Lupski J.R., J.G. Reid, C. Gonzaga-Jauregui, et al. Whole-genome sequencing ina patient with Charcot-Marie-Tooth neuropathy // N Engl J Med. 2010. Vol. 362,№ 13. P. 1181-1191.71.Familial Breast Cancer: Classification and Care of People at Risk of FamilialBreast Cancer and Management of Breast Cancer and Related Risks in Peoplewith a Family History of Breast Cancer. 2013, Cardiff UK: NationalCollaborating Centre for Cancer.72.Sinico R.A., M.L. Ribero, A. Fornasieri, et al.
Hepatitis C virus genotype inpatients with essential mixed cryoglobulinaemia // QJM. 1995. Vol. 88, № 11. P.805-810.9873.Willems M., L. Sheng, T. Roskams, et al. Hepatitis C virus and its genotypes inpatients suffering from chronic hepatitis C with or without a cryoglobulinemiarelated syndrome // J Med Virol. 1994. Vol. 44, № 3. P.
266-271.74.Frangeul L., L. Musset, P. Cresta, et al. Hepatitis C virus genotypes and subtypesin patients with hepatitis C, with and without cryoglobulinemia // J Hepatol.1996. Vol. 25, № 4. P. 427-432.75.Gerotto M., F. Dal Pero, S. Loffreda, et al. A 385 insertion in the hypervariableregion 1 of hepatitis C virus E2 envelope protein is found in some patients withmixed cryoglobulinemia type 2 // Blood. 2001. Vol.
98, № 9. P. 2657-2663.76.Bianchettin G., C. Bonaccini, R. Oliva, et al. Analysis of hepatitis C virushypervariable region 1 sequence from cryoglobulinemic patients and associatedcontrols // J Virol. 2007. Vol. 81, № 9. P. 4564-4571.77.Rigolet A., P. Cacoub, A. Schnuriger, et al. Genetic heterogeneity of thehypervariable region I of Hepatitis C virus and lymphoproliferative disorders //Leukemia. 2005. Vol. 19, № 6. P. 1070-1076.78.Ferri C., M. Pietrogrande, R. Cecchetti, et al.
Low-antigen-content diet in thetreatment of patients with mixed cryoglobulinemia // Am J Med. 1989. Vol. 87,№ 5. P. 519-524.79.Pozzato G., O. Burrone, K. Baba, et al. Ethnic difference in the prevalence ofmonoclonal B-cell proliferation in patients affected by hepatitis C virus chronicliver disease // J Hepatol. 1999. Vol. 30, № 6. P. 990-994.80.Migliorini P., S. Bombardieri, A.
Castellani, et al. HLA antigens in essentialmixed cryoglobulinemia // Arthritis Rheum. 1981. Vol. 24, № 7. P. 932-936.81.Lenzi M., M. Frisoni, V. Mantovani, et al. Haplotype HLA-B8-DR3 conferssusceptibility to hepatitis C virus-related mixed cryoglobulinemia // Blood. 1998.Vol. 91, № 6. P. 2062-2066.82.Hwang S.J., C.W. Chu, D.F. Huang, et al. Genetic predispositions for thepresence of cryoglobulinemia and serum autoantibodies in Chinese patients withchronic hepatitis C // Tissue Antigens. 2002.
Vol. 59, № 1. P. 31-37.9983.Nagasaka A., T. Takahashi, T. Sasaki, et al. Cryoglobulinemia in Japanesepatients with chronic hepatitis C virus infection: host genetic and virologicalstudy // J Med Virol. 2001. Vol. 65, № 1. P. 52-57.84.Cacoub P., C. Renou, G. Kerr, et al. Influence of HLA-DR phenotype on the riskof hepatitis C virus-associated mixed cryoglobulinemia // Arthritis Rheum. 2001.Vol.
44, № 9. P. 2118-2124.85.Amoroso A., M. Berrino, L. Canale, et al. Are HLA class II and immunoglobulinconstant region genes involved in the pathogenesis of mixed cryoglobulinemiatype II after hepatitis C virus infection? // J Hepatol. 1998. Vol. 29, № 1. P.36-44.86.De Re V., L. Caggiari, S. De Vita, et al. Genetic insights into the diseasemechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus //Dig Liver Dis. 2007. Vol. 39, Suppl 1. P.
65-71.87.Hue S., P. Cacoub, C. Renou, et al. Human leukocyte antigen class II alleles maycontribute to the severity of hepatitis C virus-related liver disease // J Infect Dis.2002. Vol. 186, № 1. P. 106-109.88.Minton E.J., D. Smillie, K.R. Neal, et al. Association between MHC class IIalleles and clearance of circulating hepatitis C virus. Members of the TrentHepatitis C Virus Study Group // J Infect Dis. 1998. Vol. 178, № 1. P. 39-44.89.Peano G., G. Menardi, A. Ponzetto, et al. HLA-DR5 antigen. A genetic factorinfluencing the outcome of hepatitis C virus infection? // Arch Intern Med.
1994.Vol. 154, № 23. P. 2733-2736.90.Lied G.A.,A. Berstad. Functional and clinical aspects of the B-cell-activatingfactor (BAFF): a narrative review // Scand J Immunol. 2011. Vol. 73, № 1. P.1-7.91.Ng L.G., C.R. Mackay,F. Mackay. The BAFF/APRIL system: life beyond Blymphocytes // Mol Immunol. 2005. Vol. 42, № 7. P. 763-772.92.Tarantino G., V.D. Marco, S. Petta, et al. Serum BLyS/BAFF predicts theoutcome of acute hepatitis C virus infection // J Viral Hepat.
2009. Vol. 16, № 6.P. 397-405.10093.Toubi E., S. Gordon, A. Kessel, et al. Elevated serum B-Lymphocyte activatingfactor (BAFF) in chronic hepatitis C virus infection: association withautoimmunity // J Autoimmun. 2006. Vol. 27, № 2. P. 134-139.94.Sene D., N. Limal, P. Ghillani-Dalbin, et al. Hepatitis C virus-associated B-cellproliferation--the role of serum B lymphocyte stimulator (BLyS/BAFF) //Rheumatology (Oxford).
2007. Vol. 46, № 1. P. 65-69.95.Machida K., K.T. Cheng, V.M. Sung, et al. Hepatitis C virus induces toll-likereceptor 4 expression, leading to enhanced production of beta interferon andinterleukin-6 // J Virol. 2006. Vol. 80, № 2. P. 866-874.96.Novak A.J., D.M. Grote, S.C. Ziesmer, et al. Elevated serum B-lymphocytestimulator levels in patients with familial lymphoproliferative disorders // J ClinOncol. 2006. Vol. 24, № 6. P. 983-987.97.Ayad M.W., A.A. Elbanna, D.A. Elneily, et al. Association of BAFF -871C/TPromoter Polymorphism with Hepatitis C-Related Mixed Cryoglobulinemia in aCohort of Egyptian Patients // Mol Diagn Ther. 2015.
Vol. 19, № 2. P. 99-106.98.Gragnani L., A. Piluso, C. Giannini, et al. Genetic determinants in hepatitis Cvirus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFFpromoter and Fcgamma receptors // Arthritis Rheum. 2011. Vol.
63, № 5. P.1446-1451.99.Giannini C., L. Gragnani, A. Piluso, et al. Can BAFF promoter polymorphism bea predisposing condition for HCV-related mixed cryoglobulinemia? // Blood.2008. Vol. 112, № 10. P. 4353-4354.100. Tanaka Y., N. Nishida, M. Sugiyama, et al. Genome-wide association of IL28Bwith response to pegylated interferon-alpha and ribavirin therapy for chronichepatitis C // Nat Genet. 2009. Vol. 41, № 10. P.
1105-1109.101. Suppiah V., M. Moldovan, G. Ahlenstiel, et al. IL28B is associated with responseto chronic hepatitis C interferon-alpha and ribavirin therapy // Nat Genet. 2009.Vol. 41, № 10. P. 1100-1104.101102. Ge D., J. Fellay, A.J. Thompson, et al. Genetic variation in IL28B predictshepatitis C treatment-induced viral clearance // Nature. 2009. Vol.
461, № 7262.P. 399-401.103. Li M., X. Liu, Y. Zhou, et al. Interferon-lambdas: the modulators of antivirus,antitumor, and immune responses // J Leukoc Biol. 2009. Vol. 86, № 1. P. 23-32.104. Piluso A., C. Giannini, E. Fognani, et al. Value of IL28B genotyping in patientswith HCV-related mixed cryoglobulinemia: results of a large, prospective study //J Viral Hepat. 2013. Vol. 20, № 4.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
